Columns

EONIS Approved in US for Newborn Screening of SMA, SCID

PerkinElmer‘s EONIS system has been approved in the U.S. to be used by certified laboratories to simultaneously test newborns for spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID). The approval by the U.S. Food and Drug Administration (FDA) makes EONIS the first authorized test to…

Some Trips Cover a Distance, but Some Don’t

After high school graduation, I studied abroad through the American Institute for Foreign Study. Based in Oxford, England, our group attended classes at Balliol College and enjoyed side trips to London, Paris, Rome, and Florence, Italy. From shrimp scampi at the Mitre Inn, to rolling hills, rosy…

IVF, Embryo Screening Help SMA Carriers Have Healthy Baby

A combination of in vitro fertilization and preimplantation genetic testing helped a couple in Indonesia — both carriers of mutations causing spinal muscular atrophy (SMA) — become parents of a healthy newborn, a case study reported. Their first daughter was diagnosed with SMA at 7 months, and she died of disease-related…

Let’s Give Thanks for Our Family Caregivers All Year Long

It takes a lot to manage daily life with SMA. From the mundane to the extraordinary, everything I do — although it takes much more than just myself — requires a practiced juggling act consisting of medications, specialists, assistive technology, medical equipment, appointments, adequate rest, and helping hands.

Target the genetic root cause of the disease

Any parent who has received a spinal muscular atrophy (SMA) diagnosis for their child can tell you that early treatment is crucial. Children who receive treatment for SMA as soon as possible are more likely to achieve important motor milestones. One-time gene therapy ZOLGENSMA® (onasemnogene abeparvovec-xioi) can stop…